Spark Therapeutics Inc (ONCE) reported quarterly earnings results on Wednesday, Aug-10-2016. The company reported $-1.04 earnings per share for the quarter, missing the analyst consensus estimate by $-0.05. Analysts had a consensus of $-0.99. The company posted revenue of $1.29 million in the period, compared to analysts expectations of $1.30 million. During the same quarter in the previous year, the company posted $-0.60 EPS.
Many Wall Street Analysts have commented on Spark Therapeutics Inc. RBC Capital Mkts Initiated Spark Therapeutics Inc on Jul 12, 2016 to “Outperform”, Price Target of the shares are set at $70.Shares were Reiterated by Cantor Fitzgerald on Jun 23, 2016 to “Buy” and Lowered the Price Target to $ 94 from a previous price target of $100 .Company shares were Reiterated by SunTrust on Jun 21, 2016 to “Buy”, Firm has raised the Price Target to $ 72 from a previous price target of $64 .
Spark Therapeutics Inc closed down -1.86 points or -3.12% at $57.8 with 2,10,645 shares getting traded on Monday. Post opening the session at $60.07, the shares hit an intraday low of $57.44 and an intraday high of $61 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Aug 8, 2016, Katherine A High (director officer ) sold 500 shares at $60.15 per share price. According to the SEC, on Aug 8, 2016, Jeffrey D Marrazzo (Chief Executive Officer) sold 900 shares at $60.13 per share price. On Aug 5, 2016, Anand Mehra (director) sold 5,064 shares at $60.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Spark Therapeutics Inc. (Spark) is engaged in developing products in the field of gene therapy. Spark’s product candidate SPK-RPE65 which is in Phase III clinical trial stage targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs) caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Company’s product development portfolio includes product candidates targeting expression of genes in the liver with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.